UnitedHealth's medical benefit ratio fell 270 basis points to 86.7% in the second quarter of 2026, while Elevance Health's benefit expense ratio rose 80 basis points to 89.7% over the same three months (UnitedHealth, July 16, 2026; Elevance, July 15, 2026).

Both raised full-year guidance anyway. Two of the industry's largest pricing operations, covering close to 100 million combined medical members, moved their loss ratios in opposite directions in the same 13-week window.

Key Takeaways

  • $860 million of net favorable prior period development sits inside UnitedHealth's ratio, with the majority tied to 2026 dates of service rather than to a release of margin banked in an earlier year.
  • The year-over-year swing is roughly $930 million, from a $70 million current-year miss in Q2 2025, worth a little over 100 basis points against $86.0 billion of quarterly premium revenue.
  • Elevance's pressure is named and narrow: behavioral health, specialty pharmacy, outpatient surgery and emergency department utilization in Government businesses, with Medicare Advantage and Individual ACA ahead of plan.
  • UnitedHealth has already shed 965,000 Medicare Advantage and 380,000 Medicaid members since year-end 2025, while Elevance's comparable Medicaid exits run over the next 12 to 18 months.
  • Days claims payable of 45.4 at Elevance is down 1.2 days sequentially but up 2.9 days year over year, alongside no stated prior-year deficiency.

Two Prints, Opposite Directions, Same Week

UnitedHealth's 86.7% medical care ratio compared with 89.4% a year earlier and beat a sell-side consensus near 88.5% by close to 180 basis points. Full-year adjusted EPS guidance moved to $19.50 to $20.00 from a prior floor of at least $18.25, with revenue guidance held above $439 billion. Quarterly adjusted EPS of $6.38 landed against a consensus near $4.90, and diluted EPS of $6.04 compared with $3.74 (CNBC, July 2026).

Management named three levers: Medicare Advantage benefit redesign, tighter network management, and pricing set closer to realized cost. It told analysts 2026 Medicare trend should finish below its initial estimate of roughly 10% on a milder respiratory season, while commercial trend runs modestly above 11% (Q2 call transcript).

Elevance's 89.7% was "driven by elevated medical cost trend in Government businesses, partially offset by improved performance in Individual ACA." Health Benefits carried $42.7 billion of operating revenue, up 3%, on roughly 44.9 million medical members, down about 469,000 sequentially.

MetricUnitedHealth Q2 2026Elevance Q2 2026
Medical loss / benefit expense ratio86.7% (vs. 89.4% Q2 2025)89.7% (vs. 88.9% Q2 2025)
Direction vs. prior year−270 bps+80 bps
Adjusted EPS, quarter$6.38$7.45
Full-year adjusted EPS guidance$19.50–$20.00 (from >$18.25)At least $27.00
Primary driver named by managementMA pricing/benefit redesign plus favorable current-year completionElevated Medicaid utilization, offset by MA and ACA outperformance
Membership trendMA down 965K, Medicaid down 380K, commercial down 145K since YE2025Medical membership down ~469K sequentially

Elevance's cost pressure is specific rather than broad. Executives placed the Medicaid drivers in "previously identified areas, including behavioral health, specialty pharmacy, outpatient surgery and emergency department utilization," and said membership and acuity remain "broadly aligned with assumptions," ruling out a fresh acuity reset. CFO Mark Kaye called 2026 "the expected low point before profitability improves," with second-half Medicaid margin helped by July 1 rate updates (Forbes, July 2026).

The Distinction That Separates the Two Ratios

The disclosure doing the most actuarial work sits inside UnitedHealth's ratio rather than beside it. The release states the ratio "was affected by $860 million of net favorable prior period development, with the majority related to 2026 dates of service."

Those are two different animals. Favorable development tied to a prior calendar year releases margin built into reserves booked twelve or twenty-four months ago; it flatters the quarter by drawing on conservatism carried from an earlier period and stops once the cushion is spent. Favorable development tied to the current year's dates of service means claims incurred in 2026 are completing below the completion factors and trend assumptions used to set interim IBNR earlier in the same year. That is evidence about current pricing and utilization.

The year-earlier comparison sharpens it. In Q2 2025 UnitedHealth reported $70 million unfavorable development, with nearly all of it related to 2025 dates of service, the same current-year completion dynamic running the other way during the year its Medicare Advantage and Optum Health estimates proved optimistic.

The swing is roughly $930 million. Against UnitedHealthcare's $86.0 billion of quarterly premium revenue that is a little over 100 basis points, so close to 40% of the 270-point improvement traces to completion landing better than assumed rather than to the rate action. The remaining roughly 160 basis points is the structural piece: the 2026 Medicare Advantage rate clearing realized trend, plus the benefit redesign and network changes.

Elevance's reserve position points the other way on the same axis. Days claims payable stood at 45.4 at June 30, down 1.2 days from March but up 2.9 days year over year (Form 10-Q). A rising year-over-year claims-payable balance with no stated prior-year deficiency is consistent with reserves held conservatively against elevated Medicaid utilization rather than a company caught short by it, though that will not be testable until the 2026 accident year matures.

Both Are Shrinking, One Started Earlier

The guidance raises do not run on the same engine. Elevance raised to at least $27.00 adjusted diluted EPS and at least $6.0 billion of operating cash flow, with quarterly adjusted EPS of $7.45 beating a consensus near $6.21 by roughly 20%, helped by an approximately $0.80 per share net below-the-line benefit sitting outside the underwriting result. Carelon contributed 6% operating revenue growth and a $0.9 billion operating gain while the core Government benefit ratio moved against the company.

UnitedHealth's raise reads straight off the benefit ratio, where lower claims relative to premium flow into underwriting margin and from there to EPS. The same two-word headline covers two different mechanisms.

Membership mix explains more of the ratio gap than either ratio does on its own. UnitedHealth's Medicare Advantage membership fell 965,000 since year-end 2025 and Medicaid 380,000, partly on a planned Louisiana exit, with commercial down 145,000 and total medical membership down 525,000 sequentially. A carrier that stops writing underpriced Medicaid and marginal Medicare Advantage counties improves its blended ratio mechanically, separately from how it prices what it keeps.

Elevance is running the same play on a lag. CEO Gail Boudreaux confirmed exits from additional Medicaid markets over the next 12 to 18 months where management sees "no path to sustainable performance," describing them as "targeted portfolio actions" (InsuranceNewsNet, July 2026). The Louisiana exit and the membership shedding already ran through UnitedHealth's second quarter; Elevance's equivalents are still ahead of it, in a book where it held share and absorbed utilization through this cycle. That sequencing gap, not a difference in underwriting philosophy, carries a real share of a divergence that reads at first as one company pricing better than the other.

Further Reading

Sources